Koyfin Home > Directory > Health Care > Rigel Pharmaceuticals > Long-Term Debt / Capital

Rigel Pharmaceuticals Long-Term Debt / Capital Chart (RIGL)

Rigel Pharmaceuticals annual/quarterly Long-Term Debt / Capital from 2010 to 2020.
  • Rigel Pharmaceuticals Long-Term Debt / Capital for the quarter ending June 06, 2020 was $33m a 12.35% increase of 4m year over year
  • Rigel Pharmaceuticals Long-Term Debt / Capital for the last 12 months ending June 06, 2020 was $33m a 12.35% increase of 4m year over year
  • Rigel Pharmaceuticals Annual Long-Term Debt / Capital for 2019 was $32m a 99.92% increase of 32m from 2018
  • Rigel Pharmaceuticals Annual Long-Term Debt / Capital for 2010 was $0m
Other Ratios Metrics:
  • Rigel Pharmaceuticals Total Debt / Capital for the quarter ending September 09, 2011 was $0m a -823.31% decrease of 0m year over year
  • Rigel Pharmaceuticals Other Liabilities for the quarter ending December 12, 2018 was $1m a 91.46% increase of 1m year over year
  • Rigel Pharmaceuticals Total Debt / Equity for the quarter ending September 09, 2011 was $0m a -827.75% decrease of 0m year over year
View Chart On Koyfin

Quarterly RIGL Long-Term Debt / Capital Data

06/2020$33m
03/2020$24m
12/2019$32m
09/2019$29m
06/2019$21m
03/2019$20m
12/2010$0m
09/2010$0m
06/2010$0m
03/2010$1m

Annual RIGL Long-Term Debt / Capital Data

2019$32m
2010$0m